Kornimate/medical-research-clean huggingface dataset:
comparison of a multi-tined cannula versus a conventional cannula for cervical medial branch radiofrequency ablation in chronic neck pain

Conditions: Neck Pain; Radiofrequency Ablation; Facet Joint Pain

Summary: chronic neck pain is a common disorder for spine specialists. radiofrequency ablation of medial branches has been proven effective in selected patients for relieving pain. a newer radiofrequency ablation cannula has been developed (multi-tined), allowing perpendicular access. it is proposed as an alternative to the more technically challenging traditional approach. this study aims to compared the technical and clinical aspects of both techniques.


Eligibility criteria:
inclusion criteria: * 18 years or older * cervical neck pain at least 4/10 at rest or with activity * neck pain lasting at least 6 months and refractory to conservative treatments * neck pain is primarily axial (more than upper extremity) * success to medial branch block protocol exclusion criteria: * failure to medial branch block protocol (pain relief less than 75% on 2 occasions) * cervical neck pain less than 4/10 * neurological deficits of upper extremity * neuropathic pain of upper extremity * pregnancy or breastfeeding * inflammatory or neoplastic lesion on x-ray * neck cortisone injection in last 3 months * any medical or psychiatric condition contra-indicated for radiofrequency ablation
the rapid covid-19 triage algorithm

Conditions: COVID-19

Summary: this study is being conducted to study the use and application of a point-of-care (poc) covid-19 test developed by spartan biosciences and recently approved for clinical use by health canada. phase i of this study will determine the best route for the swabs (nasal, throat, or both), and to determine if this poc test results are comparable to the standard core-lab test results.

currently, testing for covid-19 is carried out with swabs and blood tests that are sent to hospital laboratories for analysis. with the current technology, the turnaround time for test results may take any where from 8 hours up to several days for confirmation of whether you have covid-19. this delay in diagnosis may delay care, prevent other testing modalities, consume isolation beds and deplete the valuable personal protective equipment (ppe) needed while providing treatment for patients with covid-19. using a new, health canada approved technology, we can conduct the virus genetic testing at the bedside with a nostril and throat swab, with results in under 45 minutes. this new "point-of-care (poc)" technology, if proven accurate, may help future patients receive faster and more definitive treatment. at the same time, it might help health care teams to preserve resources and optimize care for patients (example: triage use of intensive care or isolation unit beds, determine need for ppe, get quarantined staff back to front line to help with care if they are non-carriers).

Eligibility criteria:
inclusion criteria: * patients ≥ 18 yo referred to the cardiology, internal medicine, icu, cicu, csicu or race teams who have tested positive for covid-19. exclusion criteria: * patients in whom conventional covid-19 testing would not have otherwise been instituted or in whom immediate test results would not alter short-term treatment, patients with pre-existing wishes for dnr.
mycose administration for healing alzheimer neuropathy (mashiane)

Conditions: Alzheimer Disease

Summary: alzheimer's disease (ad) is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to function independently. despite the significant effort to understand the basic biology of the disease and pharmaceutical advances to develop drugs, there is no effective therapy available to treat ad or slow the disease progression. β-amyloid accumulation outside brain cells and abnormal accumulations of tau protein inside neurons are taught to be two main changes in the brain that lead to ad. progressive accumulation of β-amyloid interferes with the neuron-to-neuron communication at synapses, contributing to neural cell death. also, tau tangles block the transport of nutrients and other essential molecules into the neurons. many molecules have been shown to inhibit amyloid aggregation. the anti-amyloidogenic activity of trehalose was confirmed in both in vitro and in vivo studies and its inhibitory effects on β-amyloid formation in ad have also been demonstrated. trehalose is a non-toxic disaccharide and no dose-dependent adverse effects were seen in any of the safety studies. it can act as a chemical chaperone and stabilizes the natively folded structure of protein and also trehalose has been identified as an autophagy inducer and promotes the clearance of aggregated proteins. therefore, trehalose could be a valuable candidate for the treatment and prevention of amyloid-related disease. based on the proposed hypothesis, this study aim to investigate the potential efficacy of trehalose administration in patients with ad.

purpose of the study: a randomized, triple-blind, pilot clinical trial has been designed to evaluate the effectiveness of trehalose on reducing the symptoms in ad patients. study intervention: twenty patients with alzheimer's disease were randomly divided into an intervention and a control group. trehalose will be administrated intravenously (15 g/week) for 12 weeks in the intervention group and the control group will be received normal saline as a placebo.

Eligibility criteria:
inclusion criteria: * mini-mental state examination (mmse) score range from 10 to 23 * not having other cognitive disorders exclusion criteria: * mmse score higher than 23 or lower than 10 * the presence of other cognitive disorders which will be evaluated by clinical assessment and brain imaging * the presence of factors affecting cognitive impairment such as depression * vascular dementia and lewy body dementia * previous history of head trauma * use of alcohol and other drugs that affect cognitive functioning

Keywords: alzheimer disease trehalose clinical trial autophagy
ketones for pulmonary hypertension - effects on hemodynamics

Conditions: Pulmonary Hypertension; Ketonemia

Summary: in the present study, patients with idiopathic pulmonary hypertension (ipah) and chronic thromboembolic pulmonary hypertenion will be investigated in a randomized cross-over design with ketone infusions and placebo. invasive and non-invasive hemodynamics will be evaluated

pulmonary hypertension (ph) is a debilitating disease that affects both the pulmonary vasculature and the heart. it is associated with increased mortality and hospitalization and impairs daily life for the affected patients. despite substantial advances in treatment within the past decade the prognosis remains poor with an 1-year mortality of more than 10%.1 the pathophysiology of ph is multifactorial and can be caused by left sided cardiac disease, pulmonary pathophysiological changes in the pulmonary vessels, respiratory diseases and pulmonary embolism.the treatment is targeted at the underlying cause. hence, left sided heart disease is treated with anticongestive medications4 and respiratory disease by pulmonary medications. however, pulmonary vascular diseases such as chronic thromboembolic pulmonary hypertension (cteph) and idiopathic pulmonary arterial hypertension (ipah) are treated with pulmonary endarterectomy and vasodilators targeting the pulmonary vasculature, respectively. however, not all patients have an optimal pulmonary hemodynamic response on treatment. if patients are left with persistent pulmonary hypertension the disease may progress further and cause right heart failure which worsens the prognosis. data from a recent study conducted at the investigator's institution demonstrated 40% increase in cardiac output during infusion of the ketone body 3-hydroxybutyrate (3-ohb). intriguingly, this was associated with an increase in rv function and a decrease in the pulmonary vascular resistance of approximately 20%. in the present study, 10 patients with ipah and 10 patients with cetph will be subjected to placebo and 3-ohb infusion in a randomized cross-over design. each of the infusions will be given for 2.5 hours and cross-over will be carried out on the same day. echocardiography and right sided heart catheterization will be applied and blood will be sampled.

Eligibility criteria:
inclusion criteria: * persistent pulmonary hypertension (defined as pvr \> 3 wu, pulmonary capillary wedge pressure (pcwp) \< 15 mmhg, mean pulmonary arterial pressure (mpap) ≥25 mmhg) on the most resent right heart catheterization. * preserved left ventricular ejection fraction (\<50%) on most recent echocardiography * able to give informed consent exclusion criteria: * other significant pulmonary, mitral or aortic valve disease * other disease or treatment making subject unsuitable for study participation

Keywords: right sided heart catheterization echocardiography hemodynamics
a study in healthy subjects to evaluate bioavailability of 4 formulations of e5501

Conditions: Idiopathic Thrombocytopenic Purpura

Summary: this is a study in healthy subjects. there are two parts to the study. in the first part of the study each subject will receive a single 10mg dose of each of the four formulations of e550. based on the results from part 1, an optimal formulation will be selected for further evaluation in part 2.


Eligibility criteria:
inclusion criteria: * healthy adult men and women (age ≥ 18 to ≤ 55 years) * body mass index ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 at the time of screening and baseline of treatment period 1 * platelet count between 120 x 109/l and 300 x 109/l at baseline of each treatment period 1, 3, and 5 * women of child bearing potential must agree to use a highly effective method of contraception, other than estrogen-based hormonal contraceptives, during the treatment phase of the study. in addition, other standard criteria for healthy subjects will be used. exclusion criteria: * evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal, respiratory, endocrine, hematologic, neurologic, or psychiatric disease or abnormalities or a known history of any gastrointestinal surgery that could impact the pk of study drug * agents associated with thrombotic events (including oral contraceptives) must be discontinued within 30 days of first study drug administration * evidence of organ dysfunction or any clinically significant event or illness in the subject's medical history, e.g., history of splenectomy. * history of arterial or venous thrombosis, including partial or complete thrombosis (e.g., stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, or pulmonary embolism). known family history of hereditary thrombophilic disorders (e.g., factor v leiden, antithrombin iii deficiency, etc.) * hemoglobin less than the lower limit of normal levels. in addition, other standard criteria for healthy subjects will be used.
subjective refraction with lightfield technology

Conditions: Refractive Error Correction

Summary: the aim of this study is to test whether it is possible in principle to determine defective vision using light field technology. the measurements with this first prototype will be compared with the results of the conventional method for subjective refraction determination and those using a phoropter (vision r-800 phoropter).


Eligibility criteria:
inclusion criteria: * minimum age of 18 years * best corrected visual acuity ≥ 0.8 (logmar ≤ 0.1). * dioptric range for hypermetropia: ≤ +4.50 d. * dioptric range for myopia: ≥ -6.50 d. * dioptric range for cylinder: ≤ -2.00 d. * good general health, i.e.no systemic disease such as diabetes or rheumatism which could influence ocular health * no ocular pathology or history of (intra)ocular surgery except for cataract surgery exclusion criteria: * • contact lens wear during the days of visit * binocular vision problems (e.g. amblyopia, strabismus). * inability to follow the procedures of the investigation, such as language problems, psychological disorders and dementia

Keywords: subjective refraction phoropter lightfield technology
work-related fibromyalgia

Conditions: Fibromyalgia, Secondary

Summary: the research is about fibromyalgia prevalency in working population and searching work-related fibromyalgia.

4 different job population will be included in the study. totally 200 people wil be included and evaluated. all participants will be women. the investigators will diagnose fibromyalgia with 2016 updated diagnostic criteria and evaluate work related musculoskeletal pain with nordic musculoskeletal questionnaire.

Eligibility criteria:
inclusion criteria: * working at least 3 months in same working place exclusion criteria: * diagnosed with the other musculoskeletal diseases

Keywords: fibromyalgia musculoskeletal diseases work
prehabilitation during neoadjuvant chemoradiotherapy for rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is determine whether a trimodel prehabilitation program (combined with physical exercise, nutrition supplement and mental support) during neoadjuvant chemoradiotherapy can help patients with rectal cancer to achieve better postoperative outcomes include perioperative complication rate, functional outcomes and quality of life.

this study is a prospective, single-center, randomized control trial. including criteria were (1) age between 18 and 80 years; (2) histologically confirmed rectal adenocarcinoma；(3) performance status (ecog) 0-2; (4) undergoing/scheduled for neoadjuvant chemoradiotherapy lasting at least 4 weeks. (5) fried frailty score ≥2. patients operated as emergency, pregnant or with comodities constraining physical exercise or causing disturbance of consciousness are excluded. all particapants were recruited and randomly assigned to receive trimodel prehabilitation program or standard care. all patients were treated with an eras protocol. the primary end-point is postoperative complications within 30 days. complications were diagnosed and classified according to the clavien-dindo classification and comprehensive complication index was calculated. the secondary end-points were functional walking capacity, hospital length of stay, nutrition status, patient-reported health related quality of life and immune function markers. the study was approved by the ethics committee of zhongshan hospital, fudan university, shanghai, china. written informed consent was obtained for patients to participate the study. this study followed the consolidated standards of reporting trials (consort) reporting guideline.

Eligibility criteria:
inclusion criteria: * patients with rectal cancer undergoing/scheduled for neoadjuvant chemoradiotherapy * fried frailty score≥2 (intermediately frail or frail) * written consent informed exclusion criteria: * co-morbiditie contraindicating physical exercise or causing disturbances of conciousness (dementia, parkinson disease, previous stroke with paresis, taking carbidopa/levodopa, donepezil or antidepressants) * emergent surgery * asa grade iv-v * pregnancy (absence confirmed by serum/urine β-hcg) or breast-feeding * known drug abuse/ alcohol abuse

Keywords: prehabilitation
postoperative vegf and recurrence after colon cancer surgery

Conditions: Angiogenesis; Colon Cancer; Surgery; Recurrence; VEGF Overexpression

Summary: the purpose of this trial is to study the relationship between the angiogenic response to surgical aggression, determined through the serum levels of vascular endothelial growth factor (vegf) on postoperative day four, and the tumor recurrence in patients with colon cancer operated with a curative intention.

design: prospective multicentric study. participation: colorectal surgery units of hospital del mar, barcelona; hospital universitari joan xxiii, tarragona; hospital universitari la fe, valencia; hospital clínico san carlos, madrid; hospital general de granollers, granollers; hospital germans trias i pujol, badalona; athalaia, xarxa assistencial universitària de manresa, manresa study subjects: 280 consecutive patients with non-metastatic colon cancer in whom a curative intent resection is performed. determinations: determination of the proangiogenic cytokine vegf in serum on the postoperative day four to assess its relationship with oncological results on long-term follow-up.

Eligibility criteria:
inclusion criteria: * patients with colon cancer admitted to the colorectal surgery unit of the centers participating in the study, * patients who will undergo elective surgical resection with potentially curative intention exclusion criteria: * patients with metastatic disease * patients with synchronous colon neoplasia or in the previous five years * patients undergoing emergency surgery * patients who do not sign the informed consent.

Keywords: vegf colon cancer surgery recurrence
treatment of breast fibroadenoma with high intensity focused ultrasound (hifu)

Conditions: Breast Fibroadenoma

Summary: demonstrate the efficacy of high intensity focused ultrasound in the treatment of the breast fibroadenoma.


Eligibility criteria:
inclusion criteria: * one breast fibroadenoma with diagnosis based on: * clinical examination * ultrasound image * for women older than 35 years: mammogram with bi-rads score \< 3 * histologic confirmation by two independent readers * fibroadenoma size between 1 cm and 3 cm at its largest dimension (measured by ultrasound) exclusion criteria: * patient pregnant or lactating * bi-rads score \> 2 at the mammogram, or microcalcifications within the lesion. * history of breast cancer or history of laser or radiation therapy to the target breast * breast implants * breast cyst * fibroadenoma not clearly visible on the ultrasound images (in b mode) * patient participating in other trials using drugs or devices
one-lung ventilation during internal thoracic artery grafting in cardiac surgery

Conditions: Coronary Artery Bypass

Summary: coronary artery bypass grafting is a current cardiac surgery. internal thoracic artery is usually taking to restore coronary revascularization, and its dissection can lead to accidental or voluntary pleural effusions. respiratory complications are frequent, due to the drainage required. in this study, the investigators propose one-lung ventilation to facilitate artery grafting and surgical procedure. the investigators will include all adult patients with elective coronary artery bypass surgery (cabg) by internal thoracic artery, in a prospective, controlled, randomized and monocentric study. the main objective is to demonstrate that one-lung ventilation using ez-blocker can reduce pleural effusion defined by presence of drainage and/or pneumothorax on x-ray chest in the icu.


Eligibility criteria:
inclusion criteria: * elective cabg surgery with internal thoracic artery, with patient consent. * patient who have french social security exclusion criteria: * cardiac or thoracic past-history * polyurethane allergy * guardianship patient * endotracheal intern diameter too small to allow the ez-blocker introduction or the fiberscope * use of laser immediately near the ez-blocker

Keywords: elective surgery cabg one-lung ventilation ez blockers pleural effusion
system accuracy of bgm gl22

Conditions: Diabetes

Summary: this study assesses the system accuracy of a blood glucose monitoring system pursuant to iso 15197


Eligibility criteria:
inclusion criteria: * male or female patients with hypo-, eu- or hyperglycaemia * the written informed consent had to be signed * the volunteers must be older than 18 years * the volunteers have legal capacity and are able to understand meaning, nature and possible consequences of the procedures involved exclusion criteria: * pregnancy or lactation * acute or chronic diseases with the risk of aggravation by the measure * a current constitution that does not allow participating in the study * participation in another study or activity with the blood glucose measuring system evaluated in the present study * application of substances listed in appendix a of din en iso 15197:2015
long term safety and tolerability study of abt-089 in adults with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention-Deficit/Hyperactivity Disorder

Summary: the objective of this study is to evaluate the long-term effects and tolerability of abt-089 in adults with attention-deficit/hyperactivity disorder (adhd).


Eligibility criteria:
inclusion criteria: * the subject was randomized into study m10-346 and completed the study. * female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. * male subjects must agree to comply with applicable contraceptive requirements. * the subject is judged to be in generally good health. exclusion criteria: * the subject has taken any adhd medication between the last dose of study drug in study m10-346 and the first dose of study drug in the current study. * the subject anticipates a move outside the geographic area.

Keywords: attention-deficit/hyperactivity disorder
implementing a guidelines-based m-health intervention for high risk asthma patients

Conditions: Pediatric Asthma

Summary: the goal of this research study is to test how good an app is in making asthma easier to manage for 372 adolescents/young adults. the app is a mobile version of the asthma action plan.

the proposed project aligns with our prior work targeting high-risk pediatric asthma populations in non-inner city environments by targeting adolescents at risk for future exacerbations from the patient-centered medical home (pcmh) at arkansas children's hospital (ach). we propose to conduct a 3-arm randomized, controlled trial with 372 adolescents with uncontrolled asthma to test the effectiveness of maap. maap provides real-time, personalized feedback, asthma education, and data logging/tracking capabilities.

Eligibility criteria:
inclusion criteria: * age ≥12 and \<21 years * persistent asthma according to national guidelines criteria * asthma control test (act) score ≤19 * prescribed a preventive (controller) asthma medication in the past 6 months * access to a smartphone compatible with the peakmaap and nutrimap * access to the internet * able to read and speak english exclusion criteria: * significant underlying respiratory disease other than asthma, such as cystic fibrosis * significant co-morbid conditions, such as moderate to severe developmental delay that could interfere with the adolescent's ability to self-monitor asthma * current smoker * participation in the investigator's or other asthma clinical trials in the previous 6 months

Keywords: asthma action plan smartphone app